3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other
2
Head & Neck
2
Conditions
Lymphoma
3
Stomatitis
2
Small Cell Lung Carcinoma
2
Neoplasms
2
Mucositis
2
Mouth Neoplasms
2
Lung Neoplasms
2
Head and Neck Neoplasms
2
Carcinoma, Small Cell
2
Brain Neoplasms
2
Spinal Cord Neoplasms
1
Neuroendocrine Tumors
1
Neoplasm Metastasis
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Central Nervous System Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cisplatin
30
Magnetic Resonance Spectroscopy
21
Radiotherapy
20
pembrolizumab
18
Specimen Handling
17
Cetuximab
16
Radiotherapy, Intensity-Modulated
11
Paclitaxel
11
Carboplatin
11
Fluorouracil
10
Biopsy
10
1,2-diaminocyclohexaneplatinum II citrate
10
Radiation
9
Platinum
9
Drug Therapy
9
Taxes
7
Surgical Procedures, Operative
7
Celecoxib
7
X-Rays
6
Standard of Care
6
Sentinel Lymph Node Biopsy
6
Surveys and Questionnaires
5
Nivolumab
5
cemiplimab
4
Metformin
4
Fluorodeoxyglucose F18
4
Docetaxel
4
Chemoradiotherapy
4
(225)Ac-DOTA-c(RGDyK)
4
durvalumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Mouth Neoplasms
×
RRx-001
×
Clear all
NCT05966194
2024-11-15
KEVLARx
EpicentRx, Inc.
Phase 2
Recruiting
216 enrolled
NCT03515538
2024-11-04
PREVLAR
EpicentRx, Inc.
Phase 2
Completed
53 enrolled
15 charts